The inevitable drift to triple therapy in COPD: An analysis of prescribing pathways in the UK

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2207-2217

  Brusselle, Guy ^a,b   Price, David ^c,d   Gruffydd Jones, Kevin ^e   Miravitlles, Marc ^f   Keininger, Dorothy L ^g   Stewart, Rebecca ^d   Baldwin, Michael ^h   Jones, Rupert C ⁱ  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d Research in Real Life   (Singapore)

^e Box Surgery ^*  (United Kingdom)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g NOVARTIS PHARMA AG   (Switzerland)

^h Novartis Pharmaceuticals Limited   (United Kingdom)

ⁱ PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

Author keywords

Chronic obstructive pulmonary disease; GOLD guidelines; Observational study; Prescribing patterns; Primary care

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG THERAPY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH COUNCIL SCORE; OBSERVATIONAL STUDY; PRESCRIPTION; RESPIRATORY TRACT DISEASE ASSESSMENT; TREND STUDY; TRIPLE THERAPY; UNITED KINGDOM; CLASSIFICATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORGANIZATION AND MANAGEMENT; PRIMARY HEALTH CARE; PROTOCOL COMPLIANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; UNITED KINGDOM;

EID: 84944880515     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S91694     Document Type: Article

References (49)

1. Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188-207.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2015. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015.pdf. Accessed July 2, 2015.
3. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease; 2013. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf. Accessed July 2, 2015.
4. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Institute for Health and Care Excellence; 2004. Available from: https://www.nice.org.uk/guidance/cg101/evidence/cg101-chronic-obstructive-pulmonary-disease-update-full-guideline2. Accessed July 2, 2015.
5. Asche CV, Leader S, Plauschinat C, et al. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis. 2012;7:201-209.
6. Fitch K, Iwasaki K, Pyenson B, Plauschinat C, Zhang J. Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis. Curr Med Res Opin. 2011;27(7):1425-1429.
7. Masoompour SM, Mohammadi A, Mahdaviazad H. Adherence to the Global Initiative for Chronic Obstructive Lung Disease guidelines for management of COPD: a hospital-base study. Clin Respir J. Epub 2014 Oct 13.
8. Miravitlles M, Sicras A, Crespo C, et al. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis. 2013;7(3):139-150.
9. Canadian Agency for Drugs and Technologies in Health (CADTH). Triple Therapy for Moderate-to-Severe Chronic Obstructive Pulmonary Disease. CADTH Technol Overv. 2010;1(4):e0129.
10. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD. 2011;8(3):206-243.
11. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(9):CD009039.
12. Jochmann A, Neubauer F, Miedinger D, Schafroth S, Tamm M, Leuppi JD. General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study. Swiss Med Wkly. Epub 2010 April 21.
13. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34(1):13-16.
14. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989-997.
15. de Miguel-Díez J, Carrasco-Garrido P, Rejas-Gutierrez J, et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung. 2011;189(3):199-206.
16. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:493-501.
17. Wong GW, Miravitlles M, Chisholm A, Krishnan JA. Respiratory guidelines - which real world? Ann Am Thorac Soc. 2014;11 Suppl 2:S85-S91.
18. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-456.
19. Jones PW, Willits LR, Burge PS, Calverley PM; Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21(1):68-73.
20. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(8):1084-1091.
21. Rossi A, van der Molen T, del Olmo R, et al. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548-1556.
22. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337(1):8-14.
23. Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018-1024.
24. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-1006.
25. Weatherall M, James K, Clay J, et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy. 2008;38(9):1451-1458.
26. DiSantostefano RL, Sampson T, Le HV, Hinds D, Davis KJ, Bakerly ND. Risk of pneumonia with inhaled corticosteroid versus long-acting bronchodilator regimens in chronic obstructive pulmonary disease: a new-user cohort study. PloS One. 2014;9(5):e97149.
27. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162-166.
28. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029-1036.
29. 1. Value in Health.15(7):A560.
30. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285-1294.
31. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51-60.
32. Harries TH, Seed PT, Jones S, Schofield P, White P. Chronic obstructive pulmonary disease hospital admissions and drugs - unexpected positive associations: a retrospective general practice cohort study. NPJ Prim Care Respir Med. 2014;24:14006.
33. Optimum Patient Care Research Database (OPCRD) [webpage on the Internet]. Cambridge: Optimum Patient Care; 2014. Available from: http://www.optimumpatientcare.org/Html_Docs/OPCRD.html. Accessed July 2, 2015.
34. Yohannes AM, Connolly MJ, Hanania NA. Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013;8:117-125.
35. General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF) [webpage on the Internet]. London: British Medical Association; 2014. Available from: http://bma.org.uk/practical-support-at-work/contracts/independent-contractors/qof-guidance. Accessed July 2, 2015.
36. Miyazaki M, Nakamura H, Takahashi S, et al. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:1053-1059.
37. Burgel PR, Deslée G, Jebrak G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201-1203.
38. Papala M, Kerenidi N, Gourgoulianis KI. Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD. Prim Care Respir J. 2013;22(3):362-364.
39. Safka K, McIvor L, McIvor A. P252 Gold Category And Optimal Management: A Canadian Perspective. Thorax. 2014;69:A187-A188.
40. Calverley PM. What to use INSTEAD of inhaled corticosteroids in COPD? Eur Respir J. 2014;44(6):1391-1393.
41. Rossi A, Guerriero M, Corrado A; OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Med. 2014;15:77.
42. Brusselle GG, Bracke K, Lahousse L. Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts. Lancet Respir Med. 2015;3(6):416-417.
43. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435-442.
44. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975-981.
45. Brusselle G. Why doesn't reducing exacerbations decrease COPD mortality? Lancet Respir Med. 2014;2(9):681-683.
46. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22(1):92-100.
47. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids - implications for safety and costs: cross-sectional observational study. PloS One. 2013;8(10):e75221.
48. Sin DD, Man SF. Steroids in COPD: still up in the air? Eur Respir J. 2010;35(5):949-951.
49. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.